AP757A - Tetracyclic spiro piperidine compounds, a process for their preparation and their use as 5HT1D receptor antagonists in the treatment of CNS disorders. - Google Patents

Tetracyclic spiro piperidine compounds, a process for their preparation and their use as 5HT1D receptor antagonists in the treatment of CNS disorders. Download PDF

Info

Publication number
AP757A
AP757A APAP/P/1997/001006A AP9701006A AP757A AP 757 A AP757 A AP 757A AP 9701006 A AP9701006 A AP 9701006A AP 757 A AP757 A AP 757A
Authority
AP
ARIPO
Prior art keywords
methyl
furo
piperidine
indole
carbonyl
Prior art date
Application number
APAP/P/1997/001006A
Other languages
English (en)
Other versions
AP9701006A0 (en
Inventor
Laramie Mary Gaster
Francis David King
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426029.6A external-priority patent/GB9426029D0/en
Priority claimed from GBGB9512920.1A external-priority patent/GB9512920D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP9701006A0 publication Critical patent/AP9701006A0/xx
Application granted granted Critical
Publication of AP757A publication Critical patent/AP757A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1997/001006A 1994-12-22 1995-12-06 Tetracyclic spiro piperidine compounds, a process for their preparation and their use as 5HT1D receptor antagonists in the treatment of CNS disorders. AP757A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426029.6A GB9426029D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9512920.1A GB9512920D0 (en) 1995-06-24 1995-06-24 Novel compounds
PCT/EP1995/004889 WO1996019477A1 (en) 1994-12-22 1995-12-06 Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists

Publications (2)

Publication Number Publication Date
AP9701006A0 AP9701006A0 (en) 1997-07-31
AP757A true AP757A (en) 1999-09-06

Family

ID=26306239

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001006A AP757A (en) 1994-12-22 1995-12-06 Tetracyclic spiro piperidine compounds, a process for their preparation and their use as 5HT1D receptor antagonists in the treatment of CNS disorders.

Country Status (27)

Country Link
US (1) US5972951A (ja)
EP (1) EP0799226B1 (ja)
JP (1) JPH10510821A (ja)
CN (1) CN1175256A (ja)
AP (1) AP757A (ja)
AR (1) AR002011A1 (ja)
AT (1) ATE199085T1 (ja)
AU (1) AU697361B2 (ja)
BG (1) BG61977B1 (ja)
BR (1) BR9510419A (ja)
CA (1) CA2208244A1 (ja)
CZ (1) CZ192397A3 (ja)
DE (1) DE69520075T2 (ja)
DZ (1) DZ1957A1 (ja)
ES (1) ES2153907T3 (ja)
FI (1) FI972583A (ja)
HU (1) HUT77650A (ja)
IL (1) IL116486A0 (ja)
MA (1) MA23753A1 (ja)
MX (1) MX9704777A (ja)
NO (1) NO972910L (ja)
NZ (1) NZ298036A (ja)
OA (1) OA10610A (ja)
PL (1) PL321048A1 (ja)
SK (1) SK80297A3 (ja)
TR (1) TR199501597A2 (ja)
WO (1) WO1996019477A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519033D0 (en) * 1995-09-18 1995-11-15 Smithkline Beecham Plc Treatment
GB9522845D0 (en) * 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
US6166034A (en) * 1995-11-08 2000-12-26 Smithkline Beecham P. L. C Spiro piperidine derivatives as 5HT1D receptor antagonists
EP0862565A1 (en) * 1995-11-22 1998-09-09 Smithkline Beecham Plc Tricyclic spiro compounds as 5ht 1d? receptor antagonists
GB9605883D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9606396D0 (en) * 1996-03-27 1996-06-05 Smithkline Beecham Plc Novel compounds
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
FR2761069A1 (fr) * 1997-03-20 1998-09-25 Pf Medicament Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments
AU6123699A (en) * 1998-10-16 2000-05-08 Takeda Chemical Industries Ltd. Nitrogenous fused heterocycle compounds, process for the preparation thereof andagents containing the same
DE10051981A1 (de) 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
PL1656370T3 (pl) * 2003-06-03 2013-03-29 Melinta Subsidiary Corp Biarylowe związki heterocykliczne oraz sposoby ich wytwarzania i stosowania
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US7700808B2 (en) 2005-12-26 2010-04-20 Nissan Chemical Industries, Ltd. 1-3-bis(substituted phenyl)-3-hydroxypropan-1-one or 2-propen-1-one compound, and salt thereof
CN101801383A (zh) 2007-04-20 2010-08-11 迪赛孚尔制药有限公司 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂
EP3150589A1 (en) 2007-06-08 2017-04-05 MannKind Corporation Ire-1a inhibitors
JP5349303B2 (ja) 2007-06-27 2013-11-20 日産化学工業株式会社 ３−ヒドロキシプロパン−１−オン化合物、２−プロペン−１−オン化合物およびイソキサゾリン化合物の製造方法
NZ592275A (en) 2008-10-17 2013-04-26 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
JP5752136B2 (ja) 2009-10-14 2015-07-22 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スピロ−オキシインドール化合物のための合成方法
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
KR20240140187A (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
CA3089566A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of gastrointestinal stromal tumors
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
BR112022002609A2 (pt) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc Métodos de tratamento de tumores estromais gastrointestinais
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
CA3163053A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0533268B1 (en) 1991-09-18 2001-08-16 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY vol. 23, no. 6, pp. 679-689 (1980) P.A. CROOKS et al. 'Synthesis and analgesic properties of some conformationally restricted analogues of profado' *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 15, 22 July 1994 WASHINGTON, US pages 2253-2257, J.W. CLITHEROW et al. 'Evolution of a novel series of (N,N-dimethylamino)propyl- and piperazinylbenzanilides as the first selective 5-ht1d-antagonists' *

Also Published As

Publication number Publication date
OA10610A (en) 2002-09-06
US5972951A (en) 1999-10-26
FI972583A (fi) 1997-08-19
ATE199085T1 (de) 2001-02-15
WO1996019477A1 (en) 1996-06-27
EP0799226B1 (en) 2001-02-07
PL321048A1 (en) 1997-11-24
AU697361B2 (en) 1998-10-01
BG101715A (en) 1998-02-27
DZ1957A1 (fr) 2002-02-17
JPH10510821A (ja) 1998-10-20
NO972910L (no) 1997-08-14
CZ192397A3 (en) 1997-09-17
ES2153907T3 (es) 2001-03-16
CA2208244A1 (en) 1996-06-27
TR199501597A2 (tr) 1996-07-21
AR002011A1 (es) 1998-01-07
AU4343396A (en) 1996-07-10
DE69520075D1 (de) 2001-03-15
CN1175256A (zh) 1998-03-04
NO972910D0 (no) 1997-06-20
BG61977B1 (bg) 1998-11-30
EP0799226A1 (en) 1997-10-08
HUT77650A (hu) 1998-07-28
SK80297A3 (en) 1998-12-02
MX9704777A (es) 1997-10-31
BR9510419A (pt) 1998-05-19
FI972583A0 (fi) 1997-06-17
AP9701006A0 (en) 1997-07-31
NZ298036A (en) 1998-11-25
IL116486A0 (en) 1997-08-14
DE69520075T2 (de) 2001-08-02
MA23753A1 (fr) 1996-07-01

Similar Documents

Publication Publication Date Title
AP757A (en) Tetracyclic spiro piperidine compounds, a process for their preparation and their use as 5HT1D receptor antagonists in the treatment of CNS disorders.
JP4796698B2 (ja) 新たな薬学的に活性な化合物
CN104039784B (zh) 取代的增环嘧啶及其用途
CA2262796C (en) 4-substituted beta-carbolines as immunomodulators
JP2001505567A (ja) 心臓循環系疾患の処置のための新規な置換ピラゾール誘導体
WO2007055418A1 (ja) アザ置換スピロ誘導体
EA016079B1 (ru) Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
KR20200036913A (ko) [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
TW201305178A (zh) 作為ｍＰＧＥＳ－１抑制物的三環化合物
AU2010208863A1 (en) Fused ring compound and use thereof
CA3128846A1 (en) Difluoromethylene compound
TW200914457A (en) Pyrimidodiazepinone derivative
OA10601A (en) Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclicring
JP2008525481A (ja) 三環式δ−オピオイド・モジュレーター
JP2001220390A (ja) 縮合ピラゾール誘導体
AU2005240816A1 (en) 6-substituted pyridoindolone derivatives production and therapeutic use thereof
CZ180793A3 (en) Novel 3-oxadiazolyl-1,6-naphthyridine derivatives
EP0861257A1 (en) Spiro piperidine derivatives as 5mt receptor antagonists
RU2168510C2 (ru) Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
WO2002057255A1 (fr) Derives du pyrrole substitues en 4 ou 5
AU646343B2 (en) Heterocyclic compounds, their production and use
RU2495035C2 (ru) Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида
JPH0710881A (ja) ５−ｈｔ４受容体作動作用を有するオキサアザビシクロ誘導体
NZ613656A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation